SL-901 / UCB, Menarini - LARVOL DELTA

Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Terminated | Sponsor: Stemline Therapeutics, Inc. | Completed ➔ Terminated; The study was stopped after careful consideration of the landscape of similar drugs and evolving standard of care.

Trial termination • Oncology • Solid Tumor

Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: Stemline Therapeutics, Inc. | Recruiting ➔ Completed | N=60 ➔ 20 | Trial completion date: Dec 2023 ➔ Jun 2023 | Trial primary completion date: Dec 2023 ➔ May 2023

Enrollment change • Metastases • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor